Additionally, in vitro experiments have demonstrated that silibinin prevents the motility and invasion of PC3 prostate cancer cells through a variety of mechanisms, including an increase in E-cadherin at the cell membrane and a decrease in nuclear β-catenin [145]. Here, CDH1 is linked to prostate carcinoma.